Literature DB >> 31272321

sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events.

Isabel Gonçalves1,2, Pratibha Singh1, Christoffer Tengryd1, Michele Cavalera1, Ingrid Yao Mattisson1, Mihaela Nitulescu1, Ana Flor Persson1, Petr Volkov3, Gunnar Engström3, Marju Orho-Melander3, Jan Nilsson1, Andreas Edsfeldt1,2.   

Abstract

Background and Purpose- Cellular apoptosis is an important feature in atherosclerosis, contributing to necrotic core formation, and plaque vulnerability. Activation of the death receptor TRAIL-R2 (TNF [tumor necrosis factor]-related apoptosis-inducing ligand receptor 2) through its ligand tumor necrosis factor-relate apoptosis-inducing ligand (TRAIL), induces apoptosis in cells in vitro. sTRAIL-R2 (soluble TRAIL-R2) was recently shown to predict cardiovascular events in healthy individuals. In the present study, we explored if plaque levels of sTRAIL-R2 and sTRAIL reflect plaque apoptosis and vulnerability and if plasma levels of these markers predict future events in subjects with advanced atherosclerosis. Methods- Plasma from 558 patients and 202 carotid plaques from the Carotid Plaque Imaging Project biobank were used. sTRAIL-R2, sTRAIL, and caspase-8 levels were assessed using a Proseek Multiplex CVD96×96 assay. Active caspase-3 was measured using ELISA to assess plaque apoptosis. Plaque morphology was studied by immunohistochemistry. Inflammatory cytokines were assessed by Luminex. mRNA levels were quantified by RNA sequencing. Monocytes, T cells, B cells, and human coronary artery smooth muscle cells were used to study sTRAIL-R2 and sTRAIL release on cell apoptosis and inflammatory stimuli in vitro. Results- Plaque levels of sTRAIL-R2 and sTRAIL correlated to markers of extrinsic induced apoptosis (caspase-3 and -8). sTRAIL-R2 and sTRAIL protein expression were increased in symptomatic carotid plaques and patients with higher plasma levels of sTRAIL-R2 had a higher risk of future cardiovascular events. sTRAIL-R2 and sTRAIL were released upon activation of the extrinsic apoptosis pathway in vitro. sTRAIL-R2 and sTRAIL correlated with inflammatory cytokines, to CD68 expression and inversely to α-actin in the plaque tissue. Conclusions- The present study shows that sTRAIL-R2 and sTRAIL are associated to human plaque cell apoptosis, plaque inflammatory activity, and with symptomatic carotid plaques. Furthermore, high plasma levels of sTRAIL-R2 in plasma predict, independently, future cardiovascular events in individuals with manifest atherosclerotic disease.

Entities:  

Keywords:  apoptosis; atherosclerosis; cytokines; inflammation

Year:  2019        PMID: 31272321     DOI: 10.1161/STROKEAHA.119.024379

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  Identification of Biomarkers of Autophagy-Related Genes Between Early and Advanced Carotid Atherosclerosis.

Authors:  Yuanyuan Zhang; He Zhang
Journal:  Int J Gen Med       Date:  2022-05-31

2.  Weighted miRNA co-expression network reveals potential roles of apoptosis related pathways and crucial genes in thoracic aortic aneurysm.

Authors:  Siliang Chen; Lei Ji; Mengyin Chen; Dan Yang; Jiawei Zhou; Yuehong Zheng
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

3.  Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events.

Authors:  Pratibha Singh; Isabel Goncalves; Christoffer Tengryd; Mihaela Nitulescu; Ana F Persson; Fong To; Eva Bengtsson; Petr Volkov; Marju Orho-Melander; Jan Nilsson; Andreas Edsfeldt
Journal:  Cardiovasc Diabetol       Date:  2020-12-14       Impact factor: 9.951

Review 4.  TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.

Authors:  Katarzyna Kakareko; Alicja Rydzewska-Rosołowska; Edyta Zbroch; Tomasz Hryszko
Journal:  J Clin Med       Date:  2021-03-18       Impact factor: 4.241

5.  Common physiologic and proteomic biomarkers in pulmonary and coronary artery disease.

Authors:  Andreas Casselbrant; Artur Fedorowski; Sophia Frantz; Gunnar Engström; Per Wollmer; Viktor Hamrefors
Journal:  PLoS One       Date:  2022-03-09       Impact factor: 3.240

6.  Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.

Authors:  Daan Ceelen; Adriaan A Voors; Jasper Tromp; Dirk J van Veldhuisen; Kenneth Dickstein; Rudolf A de Boer; Chim C Lang; Stefan D Anker; Leong L Ng; Marco Metra; Piotr Ponikowski; Sylwia M Figarska
Journal:  Eur J Heart Fail       Date:  2022-01-23       Impact factor: 17.349

Review 7.  Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.

Authors:  Mieczysław Dutka; Rafał Bobiński; Wojciech Wojakowski; Tomasz Francuz; Celina Pająk; Karolina Zimmer
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.